VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01 Basel (Switzerland) and Mannheim (Germany), July 12, 2016 – VAXIMM AG, a Swiss/German biotech company focused on develo

Source URL: sunstone.eu

• Medicine
• Clinical medicine
• Cancer treatments
• Immunology
• Oncology
• Immunotherapy
• Virotherapy
• Glioblastoma
• Chemotherapy
• Immune system
• Cancer immunotherapy
• ALECSAT